Skip to main content

Table 1 Baseline Clinical characteristics

From: Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation

Characteristics Ezetimibe /simvastatin (n = 25) Rosuvastatin (n = 25) p-value
Age, years 62.5 ± 7.4 59.2 ± 8.8 0.154
Men 22 (88.0%) 21 (84.0%) 0.684
Current smoker 4 (16.0%) 5 (20.0%) 0.713
Diabetes mellitus 2 (8.0%) 3 (12.0%) 0.637
Hypertension 17 (68.0%) 10 (40.0%) 0.047
Diagnosis    0.301
 STEMI 19 (76.0%) 19 (76.0%)  
 NSTE-ACS 6 (2.0%) 6 (24.0%)  
Culprit artery of ACS    0.345
 Left anterior descending coronary 17 (68.0%) 16 (64.0%)  
 Left circumflex coronary 2 (8.0%) 0 (0%)  
 Right coronary 6 (24.0%) 8 (32.0%)  
 Ramus intermedius 0 (0%) 1 (4.0%)  
Culprit lesion PCI 24 (97.5%) 25 (100%) 0.848
Left ventricular ejection fraction (%) 52.9 ± 8.2 53.9 ± 73 0.718
Medications at the time of follow-up
 Aspirin 25 (100%) 25 (100%) 1.0
 P2Y12 inhibitors 25 (100.0%) 25 (100.0%) 1.0
 β-blockers 22 (88.0%) 19 (76.0%) 0.269
 Angiotensin II receptor blocker 12 (48.0%) 13 (52.0%) 0.777
 Calcium channel blocker 13 (52.0%) 12 (48.0%) 0.777
  1. CAD Coronary artery disease, STEMI ST-Segment elevation myocardial infarction, NSTE-ACS Non-ST-segment elevation-acute coronary syndrome, PCI Percutaneous coronary intervention